Home Cart Sign in  
Chemical Structure| 2942-42-9 Chemical Structure| 2942-42-9

Structure of 7-Nitroindazole
CAS No.: 2942-42-9

Chemical Structure| 2942-42-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

7-Nitroindazole is a competitive, reversible and non-selective NOS inhibitor.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of 7-Nitroindazole

CAS No. :2942-42-9
Formula : C7H5N3O2
M.W : 163.13
SMILES Code : O=[N+](C1=CC=CC2=C1NN=C2)[O-]
MDL No. :MFCD00022789
InChI Key :PQCAUHUKTBHUSA-UHFFFAOYSA-N
Pubchem ID :1893

Safety of 7-Nitroindazole

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H317-H319
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Description
7-Nitroindazole is a selective inhibitor of neuronal nitric oxide synthase (nNOS) and exhibits antinociceptive and cardiovascular effects. It serves as an important tool for studying the biological roles of nitric oxide in the central nervous system[1][2].

In Vitro:

Cell Line
Concentration Treated Time Description References
rat ventral hippocampus cells 1 mM 7-NI significantly increased extracellular levels of 5-HT and DA Br J Pharmacol. 2000 Jun;130(3):575-80
Rat cremaster muscle first-order arteriole 100 μM 20 min To investigate the constrictor effect of 7-nitroindazole on pressurized arterioles, results showed that 7-nitroindazole did not cause constriction of the arterioles. Br J Pharmacol. 2007 Jul;151(5):602-9

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague-Dawley rats Freely moving animal model Intraperitoneal injection 50 mg/kg Single administration 7-NI significantly increased extracellular levels of 5-HT and DA Br J Pharmacol. 2000 Jun;130(3):575-80
ICR mice SP-induced itch-associated response model Intradermal injection 10 nmol/site Single injection To investigate the effect of 7-Nitroindazole on SP-induced itch-associated responses. Results showed that 7-Nitroindazole significantly inhibited SP-induced scratching. Br J Pharmacol. 2003 Jan;138(1):202-8
Mice ENOS-deficient mice Superfusion 100 μM 60 minutes To investigate the role of nNOS in regulating leukocyte-endothelial cell interactions in eNOS-deficient mice. Results showed that 7-nitroindazole significantly increased leukocyte adhesion in eNOS?/? mice but had no effect in wild-type animals. Br J Pharmacol. 2001 Sep;134(2):305-12
Male Wistar rats 6-hydroxydopamine (6-OHDA)-induced hemi-Parkinsonian model Intraperitoneal injection 30 mg/kg Once daily for 21 days 7-Nitroindazole pre-treatment reduced L-DOPA-induced dyskinesia and increased COX2 immunoreactivity in the dorsal striatum Philos Trans R Soc Lond B Biol Sci. 2015 Jul 5;370(1672):20140190
Mice Wild-type mice and NOS-1 mutant mice Intraperitoneal injection 50 mg/kg Single dose, experiments started 30 minutes after administration To investigate the role of NO in short-term potentiation (STP) and long-term facilitation (LTF) of breathing. Results showed that 7-NI significantly attenuated or abolished STP and LTF. J Physiol. 2002 Feb 15;539(Pt 1):309-15
Mice Tail suspension model Intraperitoneal injection 50 mg/kg Daily for two weeks 7NI significantly prevented suspension-induced muscle atrophy, increased phosphorylated Foxo3a, and inhibited the increase in dephosphorylated and nuclear Foxo3a. Furthermore, upregulation of MuRF-1 and atrogin-1/MAFbx mRNA levels was abolished by 7NI treatment. J Clin Invest. 2007 Sep;117(9):2468-76

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

6.13mL

1.23mL

0.61mL

30.65mL

6.13mL

3.06mL

61.30mL

12.26mL

6.13mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories